Merck Suspends Enrollment In Phase II Trial Of Vertex Leukemia Drug Due To Heart Signal
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial that initiated in December aimed to enroll 270 adult patients, Merck tells “The Pink Sheet” DAILY. Those already enrolled may continue treatment pending a safety review.
You may also be interested in...
Second Phase Of Takeda’s Globalization Plan Calls For Partial Integration Of Millennium
The next phase of Takeda’s globalization strategy emphasizes organizational house cleaning. Millennium, which had operated as a standalone oncology outpost, will be partially integrated into Takeda R&D but the commitment to oncology in terms of resources and investment remains firm.
Merck Enhances Aura Of Cancer Research With Vertex Aurora Kinase Inhibitor Deal
VX-680 is ready to begin Phase I trials; aurora kinase inhibitor could have applicability in a number of cancer types. Merck will pay $20 mil. up front and as much as $350 mil. in milestones to Vertex.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.